Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Vaccine Response in Atopic Dermatitis
NCT02210780Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02210780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210780.